VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | AUTO1 CAR-T delivers durable remissions and low toxicity in adult ALL

Claire Roddie, MD, PhD, University College London, London, United Kingdom, discusses preliminary data from ALLCAR19 (NCT02935257), a multicenter, phase I clinical study of AUTO1, a novel second generation CD19 CAR-T product, as therapy for relapsed/refractory adult acute lymphoblastic leukemia (ALL). Results show that AUTO1 delivers durable remissions and prolonged CAR T-cell persistence with low cytokine-release syndrome or neurotoxicity in adult ALL. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter